Atricure -- ATRC -- Sell signals

Atricure (ATRC) has had some problems lately so I'm deleting it from the Barchart Van Meerten New High portfolio based on negative price momentum.

AtriCure, Inc. (ATRC) is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. Sell Factors: 60% Barchart short term technical sell signal Trend Spotter (tm) sell signal Below its 20 and 50 day moving averages 14.59% off its recent high Relative Strength Index 31.91% and dropping Jim Van Meerten is a portfolio advisor to Marketocracy Capital Management.  He shares his knowledge and experience from over 40 years of investing in stocks, mutual funds and ETFs on Barchart.com  in his daily blog -- Barchart Portfolio Blogs. Through Marketocracy Capital Management  you can have a Separately Managed Account that mirrors his Barchart Van Meerten New High portfolio.